There Are Now 50 Psychedelics Companies Listed In The U.S. – Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors.
Seelos Therapeutics Shares See Volume; Traders Circulate Seeking Alpha Report ‘Seelos Therapeutics Offers Huge Upside. AbbVie Or Johnson & Johnson Might Acquire Seelos’
https://seekingalpha.com/instablog/51307855-tradeinvestments2019/5645755-seelos-therapeutics-offers-huge-upside-abbvie-johnson-and-johnson-might-acquire-seelos
Seelos Therapeutics Shares See Volume; Traders Circulate Seeking Alpha Post ‘Seelos Therapeutics Should Be Trading Double It’s Current Stock Price As It Is Highly Likely To Be Acquired.’
https://seekingalpha.com/instablog/51307855-tradeinvestments2019/5647156-seelos-therapeutics-should-be-trading-double-current-stock-price-is-highly-likely-to-be
COVID Tests, THC Patches, Psychedelics: Xphyto Therapeutics Does it All
Image by Shameer Pk from Pixabay
Watching Shares Of Seelos Therapeutics; Seeking Alpha Reports ‘Watch For Cantor Analyst To Reiterate $10 Target On Seelos Therapeutics, The Stock Price Will Soon Explode To The Upside’
https://seekingalpha.com/instablog/51307855-tradeinvestments2019/5645739-watch-for-cantor-analyst-to-reiterate-10-target-on-seelos-therapeutics-stock-price-will-soon
Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial Results
Part A results from the trial of Seelos Therapeutics Inc’s (NASDAQ: SEEL) intranasal ketamine product candidate, SLS-002, and the clarity around the timing of the Part B data release call for a change in recommendation, according to Roth Capital.
Mid-Afternoon Market Update: Dow Gains 150 Points; Red Cat Holdings Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 0.43% to 34,949.08 while the NASDAQ fell 0.35% to 14,995.27. The S&P also fell, dropping 0.05% to 4,453.40.
Why Seelos Therapeutics Stock Is Trading Higher Today
Seelos Therapeutics Inc (NASDAQ:SEEl) is trading higher Monday after Roth Capital analyst Jonathan Aschoff upgraded the stock from Neutral to Buy and raised the price target from $2.50 to $8.
